We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

89 hedge funds and large institutions have $1.09B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q2 according to their latest regulatory filings, with 89 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $597K

Holders
89
Holders Change
+89
Holders Change %
–
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
89
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
$597K
Net Calls
-$597K
Net Calls Change
-$597K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
76
Bank of Montreal
Ontario, Canada
$259K +$282K +6,181 New
Renaissance Technologies
77
Renaissance Technologies
New York
$239K +$260K +5,701 New
Bessemer Group
78
Bessemer Group
New Jersey
$176K +$191K +4,194 New
Barclays
79
Barclays
United Kingdom
$95K +$104K +2,275 New
ILIM
80
Irish Life Investment Managers
Ireland
$84K +$91.1K +2,000 New
TC
81
Travelers Companies
Minnesota
$82K +$89.5K +1,965 New
Teacher Retirement System of Texas
82
Teacher Retirement System of Texas
Texas
$43K +$46.5K +1,020 New
TRCT
83
Tower Research Capital (TRC)
New York
$41K +$44.8K +984 New
Citigroup
84
Citigroup
New York
$24K +$25.3K +555 New
SSG
85
Summit Securities Group
New York
$21K +$22.8K +500 New
BlackRock
86
BlackRock
New York
$18K +$20K +438 New
BAM
87
Barrett Asset Management
New York
$3K +$3.6K +79 New
Envestnet Asset Management
88
Envestnet Asset Management
Illinois
$1K +$547 +12 New
PTC
89
Private Trust Company
Ohio
$1K +$684 +15 New
1 2 3
4

GEVA Hedge Fund Activity: Q2 2013 in Review

89 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2013, worth a combined $1.09B.

Buyers outnumbered sellers: 89 funds opened new GEVA positions and 0 closed out — a net gain of 89 holders — while 0 added to existing stakes and 0 trimmed.

  • 89 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $1.09B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2013.
  • 89 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2013 and 0 closed out, a net change of +89 holders.

Based on aggregated 13F filings for Q2 2013.